Study Type
Interventional - Drug
completed
STRIVE evaluated the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing major adverse cardiovascular events.
STRIVE assessed the efficacy of a novel approach to prevent and treat microvascular obstruction and reduce major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.
The objective was to determine if tPA (10 mg or 20 mg combined dose) can reduce the incidence of the composite of post-procedural myocardial blush (MBG) grade 0/1, distal embolization, failure to achieve 50% ST-segment resolution at 30 minutes post-PCI or major adverse cardiovascular events at 30 days in patients undergoing primary PCI for STEMI.
STRIVE Slides - Download PDFStudy Design
Prospective, multi-centre, double-blind, RCT
NO. of Countries
1
NO. of Sites
3
NO. of Participants
210
Study Period
2018-2025
Sponsor
PHRI
Shamir Mehta
Senior Scientist
Shamir Mehta
Senior Scientist
Shamir Mehta is a Senior Scientist with the Acute Coronary Syndrome and Interventional Cardiology research program at PHRI. He holds the Douglas A. Holder Endowed Chair and is a Professor of Medicine at McMaster University. Mehta directs the Royal College fellowship in interventional cardiology and leads the mitral and tricuspid valve transcatheter edge-to-edge repair programs at Hamilton Health Sciences and McMaster University. He completed his medical education and postgraduate training at the University of Toronto, followed by a research fellowship at McMaster University, supported by a Canadian Institutes of Health Research New Investigator Award.
At PHRI, he leads landmark clinical trials that evaluate revascularization strategies and new pharmacologic interventions for patients with acute coronary syndromes. Mehta is the Principal Investigator of the COMPLETE-2 trial, a 5,100-patient multinational study comparing physiology-guided and angiography-guided PCI strategies for treating non-culprit lesions in patients with acute coronary syndrome and multivessel coronary artery disease. This trial includes a large-scale intracoronary imaging study using optical coherence tomography to predict cardiovascular events. He also serves on the executive committee of the Librexia ACS trial, which is testing a novel Factor XIa inhibitor in acute coronary syndromes, and he is a steering committee member of OCEAN(a), focusing on targeted lowering of lipoprotein(a) with a novel small interfering RNA after acute coronary syndrome or PCI.
Dr. Mehta has published hundreds of research articles and has secured millions of dollars in peer-reviewed research grants from CIHR and industry. In 2022, he received the Canadian Cardiovascular Society’s Research Achievement Award. In 2024, he received the Canadian Association of Interventional Cardiology Outstanding Achievement Award.
Tara McCready
Program Director
Tara McCready
Program Director
Tara McCready, PhD, oversees a variety of collaborative programs at PHRI, and serves as Project Manager for PHRI research studies and registries.
She was recruited to PHRI as a Program Director for the Canadian Network and Centre for Trials Internationally (CANNeCTIN), a national network funded by the CIHR/CFI Clinical Research Initiative program to improve the prevention and treatment of cardiac and vascular diseases and diabetes.
Previously the Executive Director of the Canadian Maternal, Infant, Child and Youth Research Network, Tara holds a PhD in Biochemistry and a MBA in Technology Commercialization from the University of Alberta.
Jennifer Cunningham
Research Project Manager III
Jennifer Cunningham
Research Project Manager III
Jennifer Cunningham has more than 20 years’ experience working in research at PHRI. Starting with a few months assisting in research accounting in the then CCC Project Office in 1998, she began her PHRI career with study teams in 2000. Since then, Jennifer has had many roles at PHRI, from data management to her current role in project management; and has worked on and managed multiple studies, from large international cardiovascular, national gastrointestinal, to policy changes and vulnerable/marginalized people studies within our own local community.
